A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs Contezolid (Primary) ; Linezolid
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ABSSSI
  • Sponsors MicuRx Pharmaceuticals
  • Most Recent Events

    • 07 Oct 2016 Status changed from active, no longer recruiting to completed, as reported by a MicuRx Pharmaceuticals.
    • 03 Nov 2015 Top-line results published in a MicuRx media release.
    • 31 Aug 2015 According to a MicuRx Pharmaceuticals media release, results from this trial are expected to be available in the fourth quarter of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top